Anika Therapeutics (NASDAQ:ANIK) Releases Earnings Results, Beats Expectations By $0.39 EPS

Anika Therapeutics (NASDAQ:ANIK) released its quarterly earnings data on Wednesday. The biotechnology company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.03 by $0.39, FiscalAI reports. The business had revenue of $32.61 million during the quarter, compared to analysts’ expectations of $29.21 million. Anika Therapeutics had a negative net margin of 3.14% and a positive return on equity of 0.20%.

Here are the key takeaways from Anika Therapeutics’ conference call:

• Strong second-quarter performance: Revenue rose 16% to $32.6 million, commercial-channel revenue increased 17%, and adjusted EBITDA reached $7.1 million, the company’s highest quarterly level since 2020.
• Guidance was raised: Anika now expects 2026 total revenue growth of 5%–10%, commercial-channel growth of 12%–18%, OEM growth of 0%–5%, and an adjusted EBITDA margin of 13%–17%.
• Operational improvements are lifting profitability: Gross margin expanded to 65%, supported by manufacturing productivity, better yields, increased throughput, favorable mix, and lean initiatives; management expects margins to remain around 64% or higher in the second half.
• International OA pain-management products and regenerative solutions remained growth drivers, with Cingal up 32%, Monovisc up 24%, and Integrity year-to-date sales up approximately 39% in the quarter.
• Regulatory timing remains uncertain: Hyalofast’s FDA review is continuing after a deficiency letter, while 2027 guidance excludes the previously expected $3 million of U.S. Hyalofast revenue; management also expects second-half profitability to be lower due to OEM order timing and continued pricing pressure.

Anika Therapeutics Price Performance

Shares of ANIK opened at $18.07 on Friday. Anika Therapeutics has a 1-year low of $7.87 and a 1-year high of $18.58. The stock has a market cap of $240.51 million, a PE ratio of -66.92 and a beta of 0.23. The firm has a fifty day moving average price of $15.07 and a 200 day moving average price of $13.71.

Institutional Trading of Anika Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the company. Cetera Investment Advisers grew its stake in Anika Therapeutics by 93.1% during the 2nd quarter. Cetera Investment Advisers now owns 19,509 shares of the biotechnology company’s stock worth $206,000 after buying an additional 9,407 shares during the last quarter. Nantahala Capital Management LLC purchased a new stake in Anika Therapeutics in the third quarter valued at approximately $197,000. Bridgeway Capital Management LLC purchased a new stake in Anika Therapeutics in the second quarter valued at approximately $185,000. AQR Capital Management LLC acquired a new stake in shares of Anika Therapeutics in the first quarter valued at approximately $181,000. Finally, Oxford Asset Management LLP acquired a new stake in shares of Anika Therapeutics in the fourth quarter valued at approximately $160,000. 91.53% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on ANIK. Weiss Ratings restated a “sell (d-)” rating on shares of Anika Therapeutics in a research note on Wednesday, June 24th. Barrington Research set a $21.00 price objective on Anika Therapeutics in a research report on Thursday. Wall Street Zen downgraded Anika Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday, May 2nd. Finally, B. Riley Financial raised their target price on Anika Therapeutics from $18.00 to $21.00 and gave the stock a “buy” rating in a research report on Thursday. Two research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $21.00.

About Anika Therapeutics

Anika Therapeutics, Inc is a life sciences company specializing in the development and commercialization of hyaluronic acid–based therapeutic products. The company focuses on orthobiologics and medical devices designed to support joint health, tissue repair and surgical applications. Anika’s proprietary hyaluronan technology serves as the foundation for products aimed at alleviating pain associated with osteoarthritis and enhancing healing in musculoskeletal and ophthalmic surgeries.

The company’s core product portfolio includes injectable viscosupplements such as Monovisc® and Orthovisc®, which are indicated for the relief of knee osteoarthritis pain, as well as Euflexxa®, approved for osteoarthritis of the knee in various international markets.